Kronos Bio, Inc. (NASDAQ:KRON) Short Interest Update

Kronos Bio, Inc. (NASDAQ:KRON) was the target of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 577,700 shares, a growth of 16.5% from the December 15th total of 496,000 shares. Currently, 1.5% of the company’s stock are short sold. Based on an average daily trading volume, of 255,900 shares, the days-to-cover ratio is presently 2.3 days.

Institutional Trading of Kronos Bio

An institutional investor recently raised its position in Kronos Bio stock. Forefront Analytics LLC lifted its position in Kronos Bio, Inc. (NASDAQ:KRON) by 75.0% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 134,998 shares of the company’s stock after purchasing an additional 57,867 shares during the quarter. Forefront Analytics LLC owned approximately 0.22% of Kronos Bio worth $167,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 64.09% of the company’s stock.

Kronos Bio Price Performance

Shares of NASDAQ KRON traded down $0.02 during midday trading on Friday, hitting $0.99. 43,891 shares of the company’s stock were exchanged, compared to its average volume of 296,299. The firm’s fifty day simple moving average is $0.95 and its 200-day simple moving average is $1.02. The company has a market cap of $59.77 million, a PE ratio of -0.69 and a beta of 1.79. Kronos Bio has a twelve month low of $0.69 and a twelve month high of $1.60.

Analysts Set New Price Targets

KRON has been the subject of several analyst reports. Piper Sandler cut shares of Kronos Bio from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $6.00 to $1.00 in a report on Thursday, November 14th. TD Cowen downgraded shares of Kronos Bio from a “buy” rating to a “hold” rating in a research note on Thursday, November 14th.

Kronos Bio Company Profile

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.